论文部分内容阅读
目的观察纤溶酶治疗急性脑梗死的临床疗效和副作用。方法将入院的急性脑梗死患者随机分为纤溶酶治疗组和血塞通对照组,于治疗前、治疗后7天、14天分别进行ESS评分及PT、APTT、FIB测定及临床疗效观察。结果治疗组临床疗效及PT、APTT、FIB有明显改变,与对照组比较有显著性差异(P<0.05)。结论纤溶酶治疗急性脑梗死,疗效确切,无不良反应,值得临床应用。
Objective To observe the clinical efficacy and side effects of plasmin in the treatment of acute cerebral infarction. Methods Patients with acute cerebral infarction were randomly divided into plasmin-treated group and Xuesaitong control group. ESS score, PT, APTT, FIB and clinical efficacy were observed before treatment, 7 days and 14 days after treatment. Results The clinical efficacy, PT, APTT and FIB in the treatment group were significantly different from those in the control group (P <0.05). Conclusions Plasminogen treatment of acute cerebral infarction, curative effect is exact, no adverse reactions, it is worth clinical application.